Enhancing MRI with AI to Improve Diagnosis of Brain Disorders
Study introduces a machine-learning model to synthesize high-quality MRIs from lower-quality images .
At the intersection of AI and medical science, there is growing interest in using machine learning to enhance imaging data captured by magnetic resonance imaging (MRI) technology. Recent studies show that ultra-high-field MRI at 7 Tesla (7T) has far greater resolution and could have clinical advantages over high-field MRI at 3T in delineating anatomical structures that are important for identifying and monitoring pathological tissue, particularly in the brain.
Most clinical MRI exams in the U.S. are performed with 1.5T or 3T MRI systems. As recently as 2022, the National Institutes of Health documented only about 100 7T MRI machines being used for diagnostic imaging worldwide.
Researchers from UC San Francisco developed a machine learning algorithm to enhance 3T MRIs by synthesizing 7T-like images that approximate real 7T MRIs. Their model enhanced pathological tissue with more fidelity for clinical insights and represents a new step toward evaluating clinical applications of synthetic 7T MRI models.
The study was presented Oct. 7 at the 27th International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI).
“Our paper introduces a machine-learning model to synthesize high-quality MRIs from lower-quality images. We demonstrate how this AI system improves the visualization and identification of brain abnormalities captured by MRIs in Traumatic Brain Injury”, said senior study author Reza Abbasi-Asl, PhD, UCSF Assistant Professor of Neurology. “Our findings highlight the promise of AI and machine learning to improve the quality of medical images captured by less advanced imaging systems.”
Better to see TBI and Multiple Sclerosis with
UCSF researchers collected imaging data from patients diagnosed with mild traumatic brain injury (TBI) at UCSF. They designed and trained three neural network models to perform image enhancement and 3D image segmentation using the generated synthetic-7T MRIs from the standard 3T MRIs.
The images generated with the new models provided enhanced pathological tissue for patients with mild TBI. They selected an example region with white matter lesions and microbleeds in subcortical areas to use for comparison. They found pathological tissue was easier to see in synthesized 7T images. This was evident in the separation of adjacent lesions and the sharper contours of subcortical microbleeds. Additionally, the synthesized 7T images better captured the diverse features within white matter lesions. These observations also highlight the promise of using this technology to improve diagnostic accuracy in neurodegenerative disorders such as multiple sclerosis.
While synthesization techniques based on machine learning frameworks demonstrate remarkable performance, their application in clinical settings will require extensive validation. The researchers believe that future work should include extensive clinical assessment of the model findings, clinical rating of model-generated images, and quantification of uncertainties in the model.
Authors: Qiming Cui, Duygu Tosun, Pratik Mukherjee, Reza Abbasi-Asl
Funding: Weill Neurohub.
About UCSF Health: UCSF Health is recognized worldwide for its innovative patient care, reflecting the latest medical knowledge, advanced technologies and pioneering research. It includes the flagship UCSF Medical Center, which is a top-ranked specialty hospital, as well as UCSF Benioff Children’s Hospitals, with campuses in San Francisco and Oakland, Langley Porter Psychiatric Hospital and Clinics, UCSF Benioff Children’s Physicians and the UCSF Faculty Practice. These hospitals serve as the academic medical center of the University of California, San Francisco, which is world-renowned for its graduate-level health sciences education and biomedical research. UCSF Health has affiliations with hospitals and health organizations throughout the Bay Area. Visit www.ucsfhealth.org. Follow UCSF Health on Facebook or on Twitter.